Navigation Links
Senetek PLC Announces 2009 Annual General Meeting Voting Results

NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that shareholders had approved all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held on December 14, 2009. Voting results were as follows:

    Description of            Votes        Votes         Votes         Non-
     Matter                    For        Against       Withheld      Votes
    --------------            -----       -------       --------      -----

    Election of  Kerry
     Dukes as Director      6,165,331    1,363,208       71,963      45,300
    Receipt of Annual
     Accounts for 2008
     with Directors'
     Report, auditors'
     report on those
     accounts and
     approve the last
     report                 6,717,147      795,815       87,540      45,300
    Appointment of
     Macias Gini &
     O'Connell LLP and
     BDO Stoy Hayward
     as the Company's
     auditors for 2009      6,663,843      796,173      140,486      45,300

"We are pleased with the results of the voting and we thank our shareholders for their support" stated Frank J. Massino, Senetek Chairman and CEO.

Senetek PLC recently announced the hiring of Miller Tabak + Co., LLC as financial and strategic advisors. The Board has retained the firm to evaluate the Company's technology and business model and to make recommendations on the development of a plan that will benefit shareholders. As a result of this evaluation, Miller Tabak has made the following recommendations:

  • Consider changing the focus and direction of the Company and the current business model;
  • Identify potential business partners for merger and/or acquisition;
  • Raise additional capital.

The Company is currently in discussions with multiple investors and potential partners, however there is no assurance that these discussions will result in a completed transaction.

About Senetek PLC: Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology, most recently resulting in the development of kinetin, the active ingredient in the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites --, and -- or call 877-SENETEK (United States and Canada) or 707-259-6278 (International Locations).

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek Implements New Corporate Communication Policy
2. Senetek PLC Reports Second Quarter 2009 Financial Results
3. Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany
4. Senetek PLC Reports First Quarter 2009 Financial Results
5. Senetek PLC Reports 2008 Financial Results
6. Dynamics Group AG Publishes Research Report on Senetek
7. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
8. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
9. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
10. Senetek PLC Announces Key Personnel Appointments
11. Senetek PLC Reports 2007 Financial Results
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: